(Q39255686)

10 September 2017

Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia (English)

1 reference

10 September 2017

1 reference

10

L Galluzzi

0 references

Guido Kroemer

12

object named as

G Kroemer

0 references

David P Enot

object named as

D Enot

0 references

Pierre Fenaux

11

object named as

P Fenaux

1 reference

10 September 2017

E Lainey

1

1 reference

10 September 2017

A Wolfromm

2

1 reference

10 September 2017

N Marie

3

1 reference

10 September 2017

D Enot

4

1 reference

10 September 2017

M Scoazec

5

1 reference

10 September 2017

C Bouteloup

6

1 reference

10 September 2017

C Leroy

7

1 reference

10 September 2017

J-B Micol

8

1 reference

10 September 2017

S De Botton

9

1 reference

10 September 2017

language of work or name

English

0 references

publication date

22 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

32

1 reference

10 September 2017

37

1 reference

10 September 2017

4331-4342

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.469

10 September 2017

0 references

cites work

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Gefitinib induces myeloid differentiation of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Mitochondrial membrane permeabilization in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Deregulation of signaling pathways in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Drug combination studies and their synergy quantification using the Chou-Talalay method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Mechanisms of cytochrome c release from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Selective killing of p53-deficient cancer cells by SP600125.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Cell death assays for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Methods for the assessment of mitochondrial membrane permeabilization in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

miR-181a and miR-630 regulate cisplatin-induced cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Mitochondrial control of cell death induced by hyperosmotic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.469

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.469

1 reference

Dimensions Publication ID

10 September 2017

1028774261

0 references

Fatcat ID

release_7mdpledrdvaj5hivznn634dq4y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7mdpledrdvaj5hivznn634dq4y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference